What Strong Biotech IP Strategies Get Right And Where Weak Ones Break Down
By Gurunathan Laxmikanthan, Ph.D.
In biotech, a patent strategy is rarely just about securing a filing date. It is about preserving optionality through financing, partnering, commercialization, and eventual exit. The patent estate has to be built into the business plan, so investors can see a protected, fundable path from today’s experiment to tomorrow’s product line. As a research scientist by training and a patent attorney who advises biotech startups and venture capital firms on IP diligence, I have seen certain strategic choices consistently separate durable, diligence-ready portfolios from those that create avoidable friction.
Build IP Around Enterprise Value, Not Just The First Experiment
Investors are rarely underwriting a single experiment; they are underwriting the platform and the product line that may be built from it. The IP strategy should keep pace with iterative development, covering alternative constructs, methods of use, dosing strategies, manufacturing approaches, and commercial product classes that align with the business strategy. When the patent portfolio maps onto the commercial roadmap, the company can tell a more credible story about the business it intends to become.
A patent estate reflecting only the first data point leaves room for competitors and fails to protect improved methods, scalable manufacturing approaches, and adjacent applications. If the first experiment proves a viable concept, the portfolio should already anticipate how that concept becomes a product family.
Clean Up Ownership Before The Data Room Opens
A strong patent strategy is only as valuable as the company’s ability to control it. Investors will scrutinize assignments, university licenses, sponsored research and material transfer agreements, consultant agreements, and joint development arrangements to confirm the company owns or has exclusive rights to its core technology.
This matters especially for biotech startups emerging from academic labs or collaborative research settings, where inventorship can be unresolved, assignments missing, field-of-use rights too narrow, or sublicensing rights misaligned with the partnering strategy. These are far easier problems to fix before diligence than during a financing.
Treat The Provisional Application As A Launch Pad, Not A Parking Lot
A well-developed provisional buys a company time to refine the data package, test variants, and identify commercially relevant embodiments before committing to final claim language.
A diligence-ready portfolio has grown with the science, capturing later embodiments, improved methods, and alternative targets, rather than remaining frozen at the moment of first filing.
A thin provisional with no follow-through becomes a diligence problem. Companies struggle when they cannot show support for later claims, when key improvements were publicly disclosed before being captured in a filing, or when they have no credible answer for obvious design-arounds. Each gap leaves the business more exposed to competitors and harder to finance.
Coordinate Filings With Publications, Presentations, And Grants
Public disclosure risk often arises before a biotech company realizes it has created one. Manuscripts, conference abstracts, posters, grant applications, investor decks, and informal scientific discussions can all move faster than the patent strategy. Disclosures made before the right filings are in place can narrow the company’s own patent position or forfeit protection in key markets.
Founders do not need to stop publishing. They need a process that coordinates disclosure with filing strategy. Before public release, the company should ask what new data, variants, methods, uses, or manufacturing details it is disclosing, and whether they belong in a filing first.
Layer Claims To Block Easy Design-Arounds
A single, narrow claim is rarely enough. Biotech value often lives in a system, process, or product architecture, not a single step. Competitors will look for the narrowest path around any given claim, so the portfolio should protect the core invention, meaningful variations, and downstream commercial forms. A layered claim strategy makes it harder for a challenger to engineer around one claim and still reach the same commercial result.
For example, a cell therapy company should not rely only on a claim to the engineered cell itself. Layers around the cell source, activation protocol, genetic modification, route of administration, and manufacturing process ensure that if one claim is narrowed or invalidated, the portfolio still captures meaningful commercial territory. This is not over-lawyering. It is how scientific innovation becomes durable, defensible business value.
Run Freedom-To-Operate (FTO) Reviews Early And In Stages
Venture investors want evidence that a company has thought beyond patentability and into commercialization. A well-managed freedom-to-operate review helps show that the company is not just pursuing promising science, but also building a path to market. It signals maturity, lowers litigation risk, and allows for course corrections before financing or partnering milestones.
Companies that ignore FTO until late-stage diligence hit problems at the worst possible time: after the pitch has advanced, after significant investment, or after the product is built. The reputational cost can be as damaging as the financial one. FTO is a living review, not a one-time checkbox.
Investors are not looking for perfection. They are looking for founders who understand that science is one piece of a larger business strategy, who know where their IP gaps are, and who can articulate a credible plan to close them. The strongest biotech IP positions are not accidents; they are intentional strategies built with future diligence in mind. That intentionality is what turns scientific promise into fundable, defensible value.
About The Author:
Gurunathan Laxmikanthan, Ph.D., is a partner in Nutter’s Intellectual Property Department. He advises biotech and pharmaceutical companies, university technology transfer offices, and venture capital firms on patent prosecution, IP diligence, freedom-to-operate analysis, and strategic IP counseling across biologics, gene therapy, cell therapy, RNA interference, and other emerging therapeutic modalities.